NeuroSense Provides Update on Nasdaq Listing Compliance

NeuroSense received a Nasdaq Staff Determination on October 1, 2026 stating it failed to regain compliance with the $35 million minimum market value (MVLS) requirement, putting its shares and warrants at risk of delisting. The company will request a Nasdaq Hearings Panel hearing, which stays any delisting pending a decision; the Panel may grant up to 180 additional days to regain compliance. Separately, NeuroSense regained compliance with the $1.00 minimum bid price rule after its 1-for-20 reverse split.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.